Comparing Leqselvi vs Olumiant
| Leqselvi (deuruxolitinib) | Olumiant (baricitinib) |
|
|---|
| Leqselvi (deuruxolitinib) | Olumiant (baricitinib) |
|
|||||||
|---|---|---|---|---|---|---|---|---|---|
|
Prescription only
Prescribed for Alopecia. Leqselvi may also be used for purposes not listed in this medication guide. |
Prescription only
Prescribed for Alopecia, Rheumatoid Arthritis, COVID-19. Olumiant may also be used for purposes not listed in this medication guide. |
Related suggestions |
|||||||
| More about Leqselvi (deuruxolitinib) | More about Olumiant (baricitinib) | ||||||||
| Ratings & Reviews | |||||||||
|
Be the first to share your experience with this drug. |
Olumiant has an average rating of 8.2 out of 10 from a total of 15 ratings on Drugs.com. 87% of reviewers reported a positive effect, while 13% reported a negative effect. |
||||||||
| Side Effects Experienced by Users Side effects are reported in Drugs.com user reviews and not clinically verified. | |||||||||
|
View all Olumiant side effects |
|||||||||
| Drug Class | |||||||||
|
None |
|||||||||
| Generic Availability | |||||||||
| Pricing and Coupons * Prices are without insurance | |||||||||
|
We could not find an exact match for this medicine. Try searching the Price Guide directly. |
View all Olumiant prices |
||||||||
| Dosage Forms | |||||||||
|
N/A |
|
||||||||
| Brand Names | |||||||||
|
N/A |
N/A |
||||||||
| Half Life Drug half-life is the time required for plasma concentration to reduce to half its original value. | |||||||||
|
N/A |
12.5 hours |
||||||||
| CSA Schedule 1 View glossary of CSA terms | |||||||||
|
Unknown
CSA Schedule is unknown. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||
| Pregnancy Category | |||||||||
|
Summary unavailable. |
Summary unavailable. See the full pregnancy warnings document. |
||||||||
| Drug Interactions | |||||||||
|
No known drug interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
A total of 513 drugs are known to interact with Olumiant:
|
||||||||
| Alcohol/Food/Lifestyle Interactions | |||||||||
|
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
||||||||
| Disease Interactions | |||||||||
|
No known disease interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
|||||||||
| First Approval Date | |||||||||
|
July 25, 2024 |
May 31, 2018 |
||||||||
| WADA Class View classifications | |||||||||
|
N/A |
N/A |
||||||||
| More Information | |||||||||
| Patient Resources | |||||||||
| Professional Resources | |||||||||
|
N/A |
|||||||||
| Related Treatment Guide | |||||||||
1 The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
See also:
Kenalog-40
Kenalog-40 is a long-acting corticosteroid injection for intramuscular (into the muscle) or ...
Olumiant
Olumiant is used to treat rheumatoid arthritis, alopecia areata (hair loss), and COVID-19. Includes ...
Ozempic
Learn about Ozempic (semaglutide) for type 2 diabetes treatment, weight management, cardiovascular ...
Zilretta
Zilretta (triamcinolone injection) is used for the management of osteoarthritis pain of the knee ...
Rogaine
Rogaine (minoxidil) is used to help regrow new, thicker hair and prevent future hair loss in men ...
Litfulo
Litfulo is used to treat severe alopecia areata in adults and adolescents 12 years and older to ...
Ritlecitinib
Ritlecitinib is used to improve hair loss in adults and adolescents aged 12 and older with severe ...
Baricitinib
Baricitinib (brand name Olumiant) is used to treat rheumatoid arthritis, alopecia areata (hair ...
Minoxidil topical
Minoxidil topical is a hair loss treatment that helps regrow hair and prevent future hair loss in ...
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.